The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
•November 14, 2025
0
Why It Matters
If the $2 billion price tag per drug remains unchecked, it will continue to choke biotech innovation and limit returns for investors, while countries that streamline regulation—most notably China—could capture a disproportionate share of future drug development.
Summary
The video tackles the mounting crisis in biotechnology: the average cost of bringing a new drug to market now exceeds $2 billion, a figure that the hosts argue is stifling innovation. They trace the rise from the early days of Regeneron, when a patient trial cost roughly $10,000, to today’s $500,000 per‑patient expense, noting that no physical law mandates such escalation and that advances like AI could dramatically improve efficiency if the industry were allowed to adopt them.
Key data points include the observation that roughly one‑fifth of public biotech firms are trading at or below their cash balances, and that a wave of excess capital during the COVID‑era boom has given way to a prolonged downturn with many EV‑negative companies and a seven‑month stretch without any biotech IPOs. The hosts attribute the cost explosion to two intertwined forces: ever‑tightening FDA regulations that demand both safety and efficacy, and a highly consolidated clinical‑research‑organization (CRO) market that is slow to implement modern, cost‑saving technologies. They also highlight China’s regulatory arbitrage—faster IND approvals, parallel review processes, and lower labor costs—as a growing competitive threat.
Notable examples punctuate the discussion: the early Regeneron trial cost, the “Eram’s law” (a tongue‑in‑cheek reference to Moore’s law run backwards), and the fact that the speakers’ own company, Amplify, runs its first‑in‑human studies exclusively outside the United States. They cite the consolidation of CROs into a dozen giants that have completed roughly 40 acquisitions each over three decades, creating a structural inertia that resists the adoption of electronic trial tools mandated by regulators.
The implication for investors and founders is clear: the bottleneck is less about scientific capability and more about regulatory and incentive structures. Companies that can leverage AI, adopt lean trial designs, or relocate early‑stage studies to faster jurisdictions like China may capture the next wave of value creation. Meanwhile, policymakers and industry leaders face pressure to modernize trial standards and break the entrenched CRO oligopoly, lest the sector’s innovation pipeline dry up entirely.
Original Description
Two venture capitalists dissect why biotech burns billions while China runs trials in weeks, and why the next Genentech won't look anything like the last one. Elliot Hershberg reveals the "three horsemen" strangling drug development as costs explode to $2.5 billion per approval, while Lada Nuzhna exposes how investigator-initiated trials in Shanghai are rewriting the competitive playbook faster than American founders can file INDs. When the infrastructure that built monoclonal antibodies becomes the commodity threatening to hollow out an entire industry, the only path forward demands inventing medicines that are literally impossible to make without tools that don't exist yet, and they're betting everything on which approach survives.
Timestamps:
00:00 - The State of Biotech: Record Lows and Structural Challenges
03:00 - The Biggest Disconnect: Technology Progress vs Market Reality
06:00 - Eroom's Law: Why Drugs Cost $2 Billion and Take Longer Than Ever
10:36 - How the Biotech Industry Actually Works: From Dye Manufacturers to Drug Discovery
13:33 - China's Speed and Cost Advantage: The Geographic Arbitrage Problem
17:00 - "We Have to Invent Stuff": America's Path to Competing with China
22:24 - AI in Drug Development: Can It Make a $2.5B Drug Cost $500M?
33:00 - GLP-1s: The Drug That Gave Biotech Its Mojo Back
38:14 - What Is Aging? We'll Treat It Before We Understand It
58:00 - Where Are The Next Iconic Biotechs? Rebundling the Stack
Follow Jorge on X: https://x.com/JorgeCondeBio
Follow Lada on X: https://x.com/ladanuzhna
Follow Elliot on X: https://x.com/ElliotHershberg
Follow Erik on X: https://x.com/eriktorenberg
Stay Updated:
If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX
Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711
Follow our host: https://x.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
0
Comments
Want to join the conversation?
Loading comments...